Document is current
Any future updates will be listed below
-
Authors
Nguyen, Thanh-Mai Ngoc
Le, Ngoc-Han Hoai
Murugesan, Mohanapriya
Janarthanan, Gopinathan
Manivasagan, Panchanathan
Luu, Cuong Hung
Phan, Diep
Jang, Eue-Soon
Li, Yi
Phan, V. H. Giang
Vijayavenkataraman, Sanjairaj
Conde, João
Thambi, Thavasyappan
-
Funding
Funding for this research was provided by:
IP national support, through CHRC (04923/2020)
National Research Foundation of Korea ((NRF-2023R1A2C1005904))
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 25 October 2025
First Online: 1 December 2025
Declarations
:
: All the animal experiments were approved by the Institutional Committees of Kyung Hee University (Approval number: KHU-22–216). The animal experiments were complied with the National Research Council's Guide for the Care and Use of Laboratory Animals.
: J.C. is a co-founder and shareholder of TargTex S. A. -Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) Consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US), and the Scientific Advisory Board of Vector Bioscience, Cambridge. The other authors declare no competing financial interests and have approved the final submission.
